Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
AKTS
AKTS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AKTS News
Wall Street Analysts Adjust Ratings on Key Stocks
1d ago
Benzinga
FDA Grants Fast Track Designation to AKY-1189 for Urothelial Cancer Treatment
Feb 24 2026
Newsfilter
2026 IPO Market Starts Steadily with $2.6 Billion Raised
Feb 04 2026
renaissancecapital
2026 IPO Market Starts Steadily with $2.6 Billion Raised
Feb 04 2026
renaissancecapital
Wall Street Analysts Adjust Ratings
Feb 03 2026
Benzinga
Helen Kim Acquires 835,000 Shares of AKTS for $15.03M Investment
Jan 13 2026
NASDAQ.COM
Aktis Oncology Closes Upsized IPO Raising $365.4 Million
Jan 13 2026
Globenewswire
Aktis Oncology Prices Upsized IPO at $1 Billion Market Cap, Closes +24%
Jan 11 2026
renaissancecapital
Aktis Oncology Prices Upsized IPO at $318 Million, Targets Solid Tumors
Jan 10 2026
renaissancecapital
Vida Ventures Supports Aktis IPO, Raising $318 Million
Jan 09 2026
Newsfilter
Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly
Jan 09 2026
renaissancecapital
Aktis Oncology Raises $318 Million at $18 per Share in IPO
Jan 09 2026
renaissancecapital
Aktis Oncology Prices Upsized IPO at $18.00 per Share, Raising $318 Million
Jan 09 2026
Globenewswire
Aktis Oncology Prices Upsized IPO at $18.00, Expected to Raise $318 Million
Jan 09 2026
Yahoo Finance
Aktis Oncology Plans $300 Million IPO, Targeting $960 Million Market Cap
Jan 07 2026
renaissancecapital
Aktis Oncology Plans to Raise $200 Million for Cancer Drug Development
Jan 05 2026
renaissancecapital
Show More News
